MS and Emerging Environmental Contaminants
The environment and possible contaminants will take center stage in a Wednesday afternoon session at the 57th annual ASMS Conference in Philadelphia, Pennsylvania.
The environment and possible contaminants will take center stage in a Wednesday afternoon session at the 57th annual ASMS Conference in Philadelphia, Pennsylvania.
With such a concerted effort from today’s society to “Go Green,” topics ranging from illicit drugs in wastewater to analysis of pharmaceuticals found in fish will be discussed in the fifth day of the technical program at the conference.
Susan Richardson from the U.S. EPA, Athens, Georgia will kick off the session with an invited overview talk on emerging environmental contaminants.
Later on in the session, a group from Baylor University will give a presentation on “Liquid Chromatography Accurate Mass Spectrometry Screening Analysis of Pharmaceuticals in Fish Collected from Effluent-Dominated Streams.”
Alejandro J. Ramirez, C. Kevin Chambliss, and Bryan W. Brooks work will look at how Key experimental methodology is developed for easy screening of pharmaceuticals in fish tissue.
Wrapping up the session is a group consisting of members from NASA (Kathleen Brooks Loftin and Timothy P. Griffin), the University of Central Florida (Christian A. Clausen III), and JEOL USA, Inc. (Robert B. Cody and John Dane). The diversified group will discuss “A Novel Technique Utilizing SBSE and DART-TOF for the Analysis of Pharmaceutical and Pesticide Contaminants in Aqueous Media.”
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
